OSLO, Norway, Oct. 26, 2018 /PRNewswire/ --
Targovax ASA (OSE: TRVX, Targovax), a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors, will announce its third quarter 2018 results on Thursday, 1 November 2018 at 07:00 CET.
The results report, and the presentation will be available at www.targovax.com in the investors section from 07:00 CET.
Øystein Soug, Chief Executive Officer of Targovax, will host an online presentation
For an elaborate presentation of the Targovax strategy, please visit targovax.com for a replay of the 15 October 2018 Capital Markets Day.
For further information, please contact:Renate Birkeli, Investor RelationsPhone: +47-922-61-624Email: firstname.lastname@example.org Media and IR enquires:Andreas Tinglum - Corporate Communications (Norway)Phone: +47-9300-1773Email: email@example.com Simon Conway/Stephanie Cuthbert - FTI Consulting (International)Phone: +44-20-3727-1000Email: Targovax@fticonsulting.com
This information was brought to you by Cision http://news.cision.com
View original content:http://www.prnewswire.com/news-releases/targovax-asa-announcement-of-third-quarter-2018-financial-results-300738563.html
Subscribe to our Free Newsletters!